By Jef Feeley and Margaret Cronin Fisk
Jan. 19 (Bloomberg) -- Johnson & Johnson agreed to settle Texas officials’ claims that the drugmaker fraudulently marketed its Risperdal anti-psychotic drug and end a trial over the allegations, people familiar with the case said. The settlement will be announced in court today, the people said.
Thursday, January 19, 2012
J&J Said to Settle Texas Risperdal Anti-Psychotic Drug Case - Businessweek